HSA binding of HIV protease inhibitors: A high-performance affinity chromatography study

Journal of Separation Science

Volumn 32, Issue 10, 2009, Pages 1625-1631

  Bertucci, Carlo ^a   Pistolozzi, Marco ^a   Felix, Guy ^b   Danielson, U Helena ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b AIX MARSEILLE UNIVERSITÉ   (France)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affinity chromatography; Circular dichroism; Drug protein binding; HIV protease inhibitors; Human serum albumin

Indexed keywords

AFFINITY CHROMATOGRAPHY; CHEMOTHERAPY; CIRCULAR DICHROISM SPECTROSCOPY; DICHROISM; DISEASES; PROBES; PROTEINS;

BINDING CAPACITIES; BINDING MECHANISMS; DRUG-PROTEIN BINDING; ELUTION EXPERIMENTS; HIGH-PERFORMANCE AFFINITY CHROMATOGRAPHY; HIV-PROTEASE INHIBITORS; HUMAN SERUM ALBUMINS; INDUCED CIRCULAR DICHROISM;

BINDING SITES;

AMPRENAVIR; ATAZANAVIR; BILIRUBIN; HUMAN SERUM ALBUMIN; IBUPROFEN; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SALICYLIC ACID; SAQUINAVIR; VALPROIC ACID;

AFFINITY CHROMATOGRAPHY; ARTICLE; BINDING COMPETITION; BINDING SITE; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ELUTION; HIGH PERFORMANCE AFFINITY CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RETENTION TIME; SPECTROSCOPY; TIME;

EID: 67649985755     PISSN: 16159306     EISSN: 16159314     Source Type: Journal    
DOI: 10.1002/jssc.200900051     Document Type: Article

References (23)

1. Hodgson, J., Nat. Biotechnol. 2001, 19, 722-726.
2. Kassel, D. B., Curr. Opin. Chem. Biol. 2004, 8, 339-345.
3. Kerns, E. H., Di, L., Drug Discov. Today. 2003, 8, 316-323.
4. Bean, P., Patnaik, M., Graziano, F. M., Aziz, D. C., Am. Clin. Lab. 2000, 19, 20-22.
5. Cimitan, S., Lindgren, M. T., Bertucci, C., Danielson, U. H., J. Med. Chem. 2005, 48, 3536-3546.
6. Schön, A., del Mar Ingaramo, M., Freire, E., Biophys. Chem. 2003, 105, 221-230.
7. Aubry, A. F., Markoglou, N., Descorps, V., Felix, G., Wainer, I. W., J. Chromatogr. 1994, 695, 1-6.
8. Hage, D. S., J. Chromatogr., B. 2002, 768, 3-30.
9. Bertucci, C., Domenici, E., Curr. Med. Chem. 2002, 9, 1463-1481.
10. Sudlow, G., Birkett, D. J., Wade, D. N., Mol. Pharmacol. 1975, 11, 59-67.
11. Noctor, T. A., Diaz-Perez, M. J., Wainer, I. W., J. Pharm. Sci. 1993, 82, 675-676.
12. Ascoli, G. A., Bertucci, C., Salvadori, P., Biomed. Chromatogr. 1998, 12, 248-254.
13. Yang, J., Hage, D. S., J. Chromatogr., A. 1996, 725, 273-285.
14. Peters, T., Jr., Ed., All About Albumin: Biochemistry, Genetics and Medical Application, Academic Press, New York 1996.
15. AHFS Drug Information 2007, p. 625.
16. Le Tiec, C., Barrail, A., Goujard, C., Taburet, A. M., Clin. Pharmacokinet. 2005, 44, 1035-1050.
17. AHFS Drug Information 2007, p. 667.
18. FDA Kaletra Prescribing Information, September 2007, p. 9.
19. AHFS Drug Information 2007, p. 676.
20. Hoggard, P. G., Owen, A., J. Antimicrob. Chemother. 2003, 51, 493-496.
21. Boffitto, M., Sciola, K., Raiteri, R., Bonora, S., Hoggard, P. G., Back, D. J., Di Perri G., Drug Metab. Dispos. 2002, 30, 859-860.
22. Bocedi, A., Notari, S., Menegatti, E., Fanali, G., Fasano, M., FEBS J. 2005, 272, 6287-6296.
23. Fanali, G., Bocedi, A., Ascenzi, P., Fasano, M., FEBS J. 2007, 274, 4491-4502.